{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"JNJ","limit":50},"count":50,"signals":[{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"phabetical) | | | | | | | 123 | Annual Meeting attendance | 22 | Corporate governance highlights | 59 | Long-term incentives | 102 | Severance benefits | | | 77 | Anti-pledging, hedging policy | 36 | Cybersecurity | 123 | Notice and access | 38 | Shareholder engagement | | | 117 | Auditor fees | 16 | Director biographies | 57 | Pay for performance | 119 | Shareholder proposal | | | 117 | Auditor tenure","filed_date":"2026-03-11","accession":"0000200406-26-000063","full_text":"https://origin.rootz.global/static/filing/0000200406-26-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":108,"context":"he 12 nominees named in this Proxy Statement to serve as Directorsfor the comingyear. | | FOR each Directornominee | Page 12 | | | | | | | | | | 2 | | | | | | | Vote, on an advisory basis, to approve named executive officercompensation. | | FOR | Page 48 | | | | | | | | | | 3 | | | | | | | Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2026. | | FOR | Page 1","filed_date":"2026-03-11","accession":"0000200406-26-000063","full_text":"https://origin.rootz.global/static/filing/0000200406-26-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":58,"context":"ials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. Patents The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licens","filed_date":"2026-02-11","accession":"0000200406-26-000016","full_text":"https://origin.rootz.global/static/filing/0000200406-26-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"al of $9.2 billion. For additional details on borrowings, see Note 7 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.5 billion which closed on April 2, 2025, and for general corporate purposes. Considering recent market conditions, the Company has re-evaluated its operating cash flows and liquidity profile and do","filed_date":"2026-02-11","accession":"0000200406-26-000016","full_text":"https://origin.rootz.global/static/filing/0000200406-26-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"ing attendance | | | 110 | CEO pay ratio | | | 70 | CEO performance evaluation | | | 75 | Compensation consultant | | | 56 | Compensation summary | | | 23 | Corporate governance highlights | | | 38 | Cybersecurity | | | 17 | Director biographies | | | 44 | Director independence | | | 24 | Director overboarding policy | | | 14 | Director qualifications | | | 39 | Environmental, social and governance | |","filed_date":"2025-03-12","accession":"0000200406-25-000099","full_text":"https://origin.rootz.global/static/filing/0000200406-25-000099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":112,"context":"hat accompanied your proxy materials. | | | | | 1 | Elect the 11 nominees named in this Proxy Statement to serve as Directors for the coming year. | | | | | 2 | Vote, on an advisory basis, to approve named executive officercompensation. | | | | | 3 | Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025. | | | | | 4-5 | Vote on the two shareholder proposals co","filed_date":"2025-03-12","accession":"0000200406-25-000099","full_text":"https://origin.rootz.global/static/filing/0000200406-25-000099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":58,"context":"ials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. Patents The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licens","filed_date":"2025-02-13","accession":"0000200406-25-000038","full_text":"https://origin.rootz.global/static/filing/0000200406-25-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"e results of operations of these acquisitions have been included in the Companys financial statements from their respective dates of acquisition.  During the fiscal year 2024, certain businesses were acquired for $15.1billion, net of cash acquired. The fiscal year 2024 acquisitions primarily included; Ambrx Biopharma, Inc., Shockwave Medical Inc., and Proteologix, Inc. The remaining acquisitions were not materi","filed_date":"2025-02-13","accession":"0000200406-25-000038","full_text":"https://origin.rootz.global/static/filing/0000200406-25-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ing attendance | | | 113 | CEO pay ratio | | | 73 | CEO performance evaluation | | | 78 | Compensation consultant | | | 59 | Compensation summary | | | 24 | Corporate governance highlights | | | 39 | Cybersecurity | | | 17 | Director biographies | | | 47 | Director independence | | | 25 | Director overboarding policy | | | 14 | Director qualifications | | | 42 | Diversity, equity and inclusion | | | 40","filed_date":"2024-03-13","accession":"0000200406-24-000024","full_text":"https://origin.rootz.global/static/filing/0000200406-24-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":110,"context":"hat accompanied your proxy materials. | | | | | 1 | Elect the 13 nominees named in this Proxy Statement to serve as Directors for the coming year. | | | | | 2 | Vote, on an advisory basis, to approve named executive officercompensation. | | | | | 3 | Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024. | | | | | 4-5 | Vote on the two shareholder proposals co","filed_date":"2024-03-13","accession":"0000200406-24-000024","full_text":"https://origin.rootz.global/static/filing/0000200406-24-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":60,"context":"ials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. Patents  The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licen","filed_date":"2024-02-16","accession":"0000200406-24-000013","full_text":"https://origin.rootz.global/static/filing/0000200406-24-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":25,"context":"tely-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).  During the fiscal year 2022, certain businesses were acquired for $17.7billion in cash and $1.1billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financi","filed_date":"2024-02-16","accession":"0000200406-24-000013","full_text":"https://origin.rootz.global/static/filing/0000200406-24-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"applicable. 1.23Payment Method means, with respect to an amount due upon a Payment Event, (a) a lump sum payment on the applicable Payment Commencement Date or (b) payment in the form of annual installments, with (i) the first installment to be paid on the Payment Commencement Date and (ii) subsequent installments to be paid on each anniversary of the Payment Commencement  2 Exhibit 10.1 Date until","filed_date":"2023-11-27","accession":"0000200406-23-000105","full_text":"https://origin.rootz.global/static/filing/0000200406-23-000105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"l Election Sub-Account, as elected by the Participant on a Deferral Election Form or by Subsequent Election. 1.22Payment Event means, with respect to a Deferral Election Sub-Account, the Participants Separation from Service or elected In-Service Payment Date, as applicable. 1.23Payment Method means, with respect to an amount due upon a Payment Event, (a) a lump sum payment on the applicable Payment Commencement","filed_date":"2023-11-27","accession":"0000200406-23-000105","full_text":"https://origin.rootz.global/static/filing/0000200406-23-000105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"other events or developments shall have occurred prior to the Separation that, in the judgment of the board of directors of J&J, would result in the Separation or the Initial Public Offering having a material adverse effect on J&J or the shareholders of J&J.  (i) Kenvue shall have entered into the Underwriting Agreement and all conditions to the obligations of Kenvue and the Underwriters thereunder shall have been satis","filed_date":"2023-05-08","accession":"0001193125-23-138287","full_text":"https://origin.rootz.global/static/filing/0001193125-23-138287.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"er in an administrative or faculty role) | | | | | | | | | | | | | | Digital | | Experience or expertise in the use and deployment of digital technologies to facilitate business objectives, including cybersecurity and data privacy | | | | | | | | | | | | | | Executive Leadership | | Senior management position, including as chief executive officer, at a large publicly-traded or private company, or other","filed_date":"2023-03-15","accession":"0000200406-23-000023","full_text":"https://origin.rootz.global/static/filing/0000200406-23-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":132,"context":"| February 28, 2023 | | | 1. | Elect the 12 nominees named in this Proxy Statement to serve as directors for the coming year; | | | | | | | | VOTING | | | 2. | Vote, on an advisory basis, to approve named executive officer compensation; | | You are eligible to vote if you were a shareholder of record at the close of business on February 28, 2023. Ensure that your shares are represented at the meeting by voting in one o","filed_date":"2023-03-15","accession":"0000200406-23-000023","full_text":"https://origin.rootz.global/static/filing/0000200406-23-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":14,"context":"egulations by the Securities and Exchange Commission. Risks Related to the Companys Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Companys Consumer Health Business Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward","filed_date":"2023-02-16","accession":"0000200406-23-000016","full_text":"https://origin.rootz.global/static/filing/0000200406-23-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"ials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. Patents  The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licen","filed_date":"2023-02-16","accession":"0000200406-23-000016","full_text":"https://origin.rootz.global/static/filing/0000200406-23-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":27,"context":"ely, and intangible assets and goodwill, net for fiscal years 2022 and 2021 of $93,556 and $81,638, respectively. 18.Acquisitions and Divestitures During the fiscal year 2022, certain businesses were acquired for $17.7billion in cash and $1.1billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financi","filed_date":"2023-02-16","accession":"0000200406-23-000016","full_text":"https://origin.rootz.global/static/filing/0000200406-23-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"er in an administrative or faculty role) | | | | | | | | | | | | | | Digital | | Experience or expertise in the use and deployment of digital technologies to facilitate business objectives, including cybersecurity and data privacy | | | | | | | | | | | | | | Executive Leadership | | Senior management position, including as chief executive officer, at a large publicly-traded or private company, or other","filed_date":"2022-03-16","accession":"0000200406-22-000026","full_text":"https://origin.rootz.global/static/filing/0000200406-22-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":115,"context":"| | | | | | | | | Items of Business | | | | | | | | | 1. Elect the 14 nominees named in this Proxy Statement to serve as Directors for the coming year | | | 2. Vote, on an advisory basis, to approve named executive officer compensation | | | 3. Approval of Company's 2022 Long-Term Incentive Plan | | | 4. Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2022 |","filed_date":"2022-03-16","accession":"0000200406-22-000026","full_text":"https://origin.rootz.global/static/filing/0000200406-22-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"ials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. Patents  The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licen","filed_date":"2022-02-17","accession":"0000200406-22-000022","full_text":"https://origin.rootz.global/static/filing/0000200406-22-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"0 of $81,638 and $89,795, respectively. 18.Acquisitions and Divestitures During fiscal year 2021, the Company did not make any material acquisitions.  During fiscal year 2020, certain businesses were acquired for $7.3billion in cash and $0.4billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financia","filed_date":"2022-02-17","accession":"0000200406-22-000022","full_text":"https://origin.rootz.global/static/filing/0000200406-22-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"of Directors with or without cause | | | | Additional Governance Features | | | | Active shareholder engagement | | | | | | Code of Business Conduct | | | Annual Say on Pay advisory vote | | | | | | Cybersecurity oversight | | | Policy Against Pledging, Hedging and Short Selling of Company Stock | | | | | Enhanced litigation disclosure | | | Disclosure on drug pricing in Janssen U.S. Transparency Repo","filed_date":"2021-03-10","accession":"0000200406-21-000011","full_text":"https://origin.rootz.global/static/filing/0000200406-21-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":110,"context":"| | | | | | | | | Items of Business | | | | | | | | 1. Elect the 14 nominees named in this Proxy Statement to serve as Directors for the coming year | | | | 2. Vote, on an advisory basis, to approve named executive officer compensation | | | | 3. Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2021 | | | | 4. Vote on the four shareholder proposals contained","filed_date":"2021-03-10","accession":"0000200406-21-000011","full_text":"https://origin.rootz.global/static/filing/0000200406-21-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"ials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. Patents  The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licen","filed_date":"2021-02-22","accession":"0000200406-21-000008","full_text":"https://origin.rootz.global/static/filing/0000200406-21-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"18,766 and $17,658, respectively, and intangible assets and goodwill, net for fiscal years 2020 and 2019 of $89,795 and $81,282, respectively. 18.Acquisitions and Divestitures Certain businesses were acquired for $7.3billion in cash and $0.4billion of liabilities assumed during fiscal year 2020. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been","filed_date":"2021-02-22","accession":"0000200406-21-000008","full_text":"https://origin.rootz.global/static/filing/0000200406-21-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"| | | | Additional Governance Features | | | | Annual Say on Pay advisory vote | | | | | | Code of Business Conduct | | | Policy Against Pledging, Hedging and Short Selling of Company Stock | | | | | Cybersecurity oversight | | | Disclosure on drug pricing in Janssen U.S. Transparency Report | | | | | Enhanced litigation disclosure | | | ESG disclosure in annual Health for Humanity Report | | | | | Rob","filed_date":"2020-03-11","accession":"0000200406-20-000018","full_text":"https://origin.rootz.global/static/filing/0000200406-20-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":101,"context":"tations. | | | | | | | | Items of Business: | | | | 1. Elect the 13 nominees named in this Proxy Statement to serve as Directors for the coming year; | | | | 2. Vote, on an advisory basis, to approve named executive officer compensation; | | | | 3. Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2020; | | | | 4. Approve an amendment to our Restated Certificat","filed_date":"2020-03-11","accession":"0000200406-20-000018","full_text":"https://origin.rootz.global/static/filing/0000200406-20-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"ials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. Patents  The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licen","filed_date":"2020-02-18","accession":"0000200406-20-000010","full_text":"https://origin.rootz.global/static/filing/0000200406-20-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":41,"context":"7 million before-tax) and a $137 million benefit after-tax from the impact of tax legislation. | | | | | | | | | | | | 79 | | | | | | | 20. | Acquisitions and Divestitures | | Certain businesses were acquired for $5.8 billion in cash and $1.4 billion of liabilities assumed during 2019. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included i","filed_date":"2020-02-18","accession":"0000200406-20-000010","full_text":"https://origin.rootz.global/static/filing/0000200406-20-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":12,"context":"ssets held for sale related to the strategic collaboration with Jabil Inc. of approximately $0.2 billion. The balance as of December 30, 2018, does not include the assets held for sale related to the divestiture of the Advanced Sterilization Products (ASP) business of approximately $0.2 billion and $0.3 billion related to the strategic collaboration with Jabil Inc.  NOTE 3 INTANGIBLE ASSETS AND GOODWILL Intangi","filed_date":"2019-10-28","accession":"0000200406-19-000066","full_text":"https://origin.rootz.global/static/filing/0000200406-19-000066.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"ssets held for sale related to the strategic collaboration with Jabil Inc. of approximately $0.2 billion. The balance as of December 30, 2018, does not include the assets held for sale related to the divestiture of the Advanced Sterilization Products (ASP) business of approximately $0.2 billion and $0.3 billion related to the strategic collaboration with Jabil Inc.  NOTE 3 INTANGIBLE ASSETS AND GOODWILL Intangi","filed_date":"2019-07-29","accession":"0000200406-19-000053","full_text":"https://origin.rootz.global/static/filing/0000200406-19-000053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":34,"context":"vote IN PERSON(see Annual Meeting Attendance and Admission Ticket Procedures on page 101 of this Proxy Statement) | | | | | | | | | By order of the Board of Directors, | | | | | | | | | THOMAS J. SPELLMAN IIIAssistant General Counsel and Corporate Secretary | | | | | | | | A Message from Our Lead Director | | | | | | | | | | | | Dear Fellow Shareholders, | | | | | As our 2019 Annual Meeting approach","filed_date":"2019-03-13","accession":"0000200406-19-000013","full_text":"https://origin.rootz.global/static/filing/0000200406-19-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"al auditors to oversee financial risks facing the company, and the Regulatory Compliance Committee works closely with management to oversee risks related to compliance, product quality and safety and cybersecurity. In response to shareholder feedback, we expanded disclosure about the Board's risk oversight in this Proxy Statement, beginning on page 23. We oversee Johnson & Johnson's strategy to ensure","filed_date":"2019-03-13","accession":"0000200406-19-000013","full_text":"https://origin.rootz.global/static/filing/0000200406-19-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":92,"context":"Meeting. | | | | | | | | Items of Business: | | | | 1. Elect the 12 nominees named in this Proxy Statement to serve as Directors for the coming year; | | | | 2. Vote, on an advisory basis, to approve named executive officer compensation; | | | | 3. Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2019; | | | | 4. Vote on the two (2) shareholder proposals conta","filed_date":"2019-03-13","accession":"0000200406-19-000013","full_text":"https://origin.rootz.global/static/filing/0000200406-19-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. Patents  The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licen","filed_date":"2019-02-20","accession":"0000200406-19-000009","full_text":"https://origin.rootz.global/static/filing/0000200406-19-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":48,"context":"average cash balance in 2017. The decrease in the average balance of cash, cash equivalents and marketable securities was due to the use of cash for general corporate purposes, primarily the Actelion acquisition for $29.6 billion, net of cash acquired late in the fiscal second quarter of 2017. Interest expense in 2018 was higher as compared to 2017 due to a higher average debt balance. The average debt balance was","filed_date":"2019-02-20","accession":"0000200406-19-000009","full_text":"https://origin.rootz.global/static/filing/0000200406-19-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"r ago. The decrease in the average balance of cash, cash equivalents and marketable securities was due to the use of cash for general corporate purposes including acquisitions, primarily the Actelion acquisition for $29.6 billion, net of cash acquired late in the fiscal second quarter of 2017. Interest expense in the fiscal nine months and fiscal thirdquarter of 2018was higher as compared to the same periods a yea","filed_date":"2018-10-31","accession":"0000200406-18-000055","full_text":"https://origin.rootz.global/static/filing/0000200406-18-000055.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":12,"context":"r ago. The decrease in the average balance of cash, cash equivalents and marketable securities was due to the use of cash for general corporate purposes including acquisitions, primarily the Actelion acquisition for $29.6 billion, net of cash acquired in the fiscal second quarter of 2017. Interest expense in the first fiscal six months and fiscal secondquarter of 2018was higher as compared to the same periods a ye","filed_date":"2018-08-02","accession":"0000200406-18-000041","full_text":"https://origin.rootz.global/static/filing/0000200406-18-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":88,"context":"werful network of scientists and entrepreneurs all over the world. Our goal is to address some of the biggest health care needs of humanity. We do this by being a leader in R&D investment. In 2017 we invested $10.6 Billion in research and development, leading to the development of lifesaving and life enhancing products that make a difference for patients and consumers all over the world. We envision a world where all d","filed_date":"2018-03-14","accession":"0000200406-18-000009","full_text":"https://origin.rootz.global/static/filing/0000200406-18-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":13,"context":"ing standards by the Financial Accounting Standards Board and the Securities and Exchange Commission. | | Risks Related to the Companys Strategic Initiatives and Health Care Market Trends | | | | | | Pricing pressures resulting from trends toward health care cost containment, including the continued consolidation among health care providers, trends toward managed care, the shift toward governments increasingly be","filed_date":"2018-02-21","accession":"0000200406-18-000005","full_text":"https://origin.rootz.global/static/filing/0000200406-18-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"ials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. Patents  The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licen","filed_date":"2018-02-21","accession":"0000200406-18-000005","full_text":"https://origin.rootz.global/static/filing/0000200406-18-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"lance in 2016. The decrease in the balance of cash, cash equivalents and marketable securities was due to the use of cash for general corporate purposes including acquisitions, primarily the Actelion acquisition for $29.6 billion, net of cash acquired. Interest expense in 2017 was higher as compared to 2016. The average debt balance was $30.9billion in 2017 versus $23.5billion in 2016. The total debt balance at th","filed_date":"2018-02-21","accession":"0000200406-18-000005","full_text":"https://origin.rootz.global/static/filing/0000200406-18-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":96,"match_count":12,"context":"nting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission. Risks related to the Companys strategic initiatives and healthcare market trends Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward","filed_date":"2025-02-13","accession":"0000200406-25-000038","full_text":"https://origin.rootz.global/static/filing/0000200406-25-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":94,"match_count":8,"context":"and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected; The Companys ability to realize the anticipated benefits from the separation of Kenvue Inc. (Kenvue).  Risks related to economic conditions, financial markets and operating internationally The risks associated with global operations on the Company and its customers and suppliers","filed_date":"2024-10-23","accession":"0000200406-24-000096","full_text":"https://origin.rootz.global/static/filing/0000200406-24-000096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":88,"match_count":11,"context":"regulations by the Securities and Exchange Commission. Risks related to the Companys strategic initiatives, healthcare market trends and the planned separation of the Company's Orthopaedics Business Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward","filed_date":"2026-02-11","accession":"0000200406-26-000016","full_text":"https://origin.rootz.global/static/filing/0000200406-26-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":88,"match_count":11,"context":"luded in cost of products sold and $227 million is included in other (income) expense. Total project costs of approximately $2.5 billion have been recorded since the restructuring was announced. This restructuring program was completed in the fiscal fourth quarter of 2018.  In the second quarter of 2018, the Company announced plans to implement actions across its global supply chain that are intended to enable the Com","filed_date":"2019-02-20","accession":"0000200406-19-000009","full_text":"https://origin.rootz.global/static/filing/0000200406-19-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"JNJ","company":"JOHNSON & JOHNSON","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":88,"match_count":11,"context":"le to higher sales volume, favorable mix in the business and lower selling, marketing and administrative costs. This was partially offset by higher net litigation expense of $0.7 billion and a higher restructuring charge of $0.1 billion as compared to 2015. Additionally, the fiscal year 2015 included higher gains on the sale of assets/businesses as compared to 2016.  As a percent to sales, consolidated earnings befor","filed_date":"2018-02-21","accession":"0000200406-18-000005","full_text":"https://origin.rootz.global/static/filing/0000200406-18-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"00c9314f654d2831fd6e956191d55dcdd44ddcf8f1878723dfc925ccb4b8297c","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"9346c488e777c6c6503093a86ea692cb3e16b12e45986aa247e317088ca2ebf8","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":21,"hourly_limit":500,"remaining":479,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}